Implementing and Integrating Disruptive Technologies for Commercial Benefit

20 Jan 2023
Commercializing the Therapies of the Future Track
Landmark Bio

9:00am Chair Introduction

Tom Bollenbach, Chief Technology Officer, Advanced Regenerative Manufacturing Institute (ARMI)


9:05am Presentation: Enabling a fast-to-clinic to clinic approach with rapid scale-up of a highly customized lentiviral vector drug product

  • VivoVec particle design for in vivo CAR-T applications
  • Leveraging the manufacturing platform for fast to clinic approaches
  • Process establishment and robustness at 50L scale

Branden Salinas, Senior Director, Manufacturing Sciences and Technology, Umoja Biopharma


9:20am Presentation: Accelerate Speed to Clinic and Improve Success Rate in Cell/Gene Therapy Development

Zhimei Du, Vice President, Translational Research and Early Development, Landmark Bio


9:35am Presentation: Addressing the Cell Multiplexing Problem with miCAR Cell Engineering

Sven Kili, Chief Executive Officer, Antion Biosciences


9:50am Presentation: Scaling ATMPs in a multi-therapy, multi-stakeholder, multi-site environment

  • How can digital solutions be used to increase access to ATMPs ?
  • How can clinics deal with multiple cell and gene therapies from multiple providers?
  • How do you improve communication and coordination between multiple providers to ensure patient safety?

Najib Rehman, Digital Automation Lead, ATMPS Ltd – Hataali


10:05am Closing Panel with Q&A

With all session participants


Branden Salinas
Senior Director Manufacturing Sciences and Technology
Umoja Biopharma
Najib Rehman
Digital Automation Lead
Sven Kili
Chief Executive Officer
Antion Biosciences
Thomas Bollenbach
Chief Technology Officer
Zhimei Du
Vice President, Translational Research and Early Development
Landmark Bio